Following the approval by the U.S. Food and Drug Administration (FDA) of emergency use authorization for the investigational monoclonal antibody therapy, bamlanivimab, the Centers for Medicare & Medicaid Services (CMS) announced it will cover monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency.
This content is restricted to members.
